Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

Fig. 5

The combination of early DAS remission and a strong biomarker response after DMARD start was confined to a subgroup of ACPA-negative patients that achieved SDFR.

ACPA-negative RA patients achieving SDFR are characterized by a strong biomarker response concomitant with early DAS remission (DAS4 months < 1.6). This comprised 23% of all ACPA-negative RA patients. Only RA patients with both clinical and biomarker follow-up information could be included. The distribution of the numbers of patients per group is as follows: of the 50 ACPA-negative RA patients not achieving SDFR, 16 (32%) achieved DAS4 months < 1.6, whereas 22 (48%) of the 46 ACPA-negative RA patients achieving SDFR achieved DAS4 months < 1.6. CRP, C-reactive protein; MMP, matrix metalloproteinase; SAA, serum A amyloid; SDFR, sustained DMARD-free remission

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us